WO1994008548A1 - Transfusion liquid-containing holder and prepared transfusion liquid - Google Patents
Transfusion liquid-containing holder and prepared transfusion liquid Download PDFInfo
- Publication number
- WO1994008548A1 WO1994008548A1 PCT/JP1993/001521 JP9301521W WO9408548A1 WO 1994008548 A1 WO1994008548 A1 WO 1994008548A1 JP 9301521 W JP9301521 W JP 9301521W WO 9408548 A1 WO9408548 A1 WO 9408548A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- infusion
- chamber
- vitamins
- container
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 99
- 229930003231 vitamin Natural products 0.000 claims abstract description 99
- 235000013343 vitamin Nutrition 0.000 claims abstract description 99
- 239000011782 vitamin Substances 0.000 claims abstract description 99
- 150000001413 amino acids Chemical class 0.000 claims abstract description 55
- 235000000346 sugar Nutrition 0.000 claims abstract description 50
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 37
- 239000000839 emulsion Substances 0.000 claims abstract description 27
- 238000001802 infusion Methods 0.000 claims description 89
- 235000001014 amino acid Nutrition 0.000 claims description 52
- 239000003925 fat Substances 0.000 claims description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003978 infusion fluid Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019156 vitamin B Nutrition 0.000 claims description 8
- 239000011720 vitamin B Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229930003448 Vitamin K Natural products 0.000 claims description 6
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 6
- 235000019168 vitamin K Nutrition 0.000 claims description 6
- 239000011712 vitamin K Substances 0.000 claims description 6
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 6
- 229940046010 vitamin k Drugs 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 150000002948 pantothenic acids Chemical class 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 abstract description 5
- 238000005192 partition Methods 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 description 51
- 239000002960 lipid emulsion Substances 0.000 description 39
- 235000019197 fats Nutrition 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- -1 Bitamino Natural products 0.000 description 21
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 230000001954 sterilising effect Effects 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000003995 emulsifying agent Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 239000004743 Polypropylene Substances 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 229920001155 polypropylene Polymers 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 241000233855 Orchidaceae Species 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002985 plastic film Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 238000004945 emulsification Methods 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000008344 egg yolk phospholipid Substances 0.000 description 5
- 229940068998 egg yolk phospholipid Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920006255 plastic film Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 229930182844 L-isoleucine Natural products 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 235000020957 pantothenol Nutrition 0.000 description 4
- 239000011619 pantothenol Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 229960002898 threonine Drugs 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 229930195722 L-methionine Natural products 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 229950001574 riboflavin phosphate Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BTLPCOOVNVTENY-UHFFFAOYSA-N 8L8 Natural products CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCCC=CCC=CCCCCC BTLPCOOVNVTENY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000005001 laminate film Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 239000001120 potassium sulphate Substances 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940035024 thioglycerol Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- OCJAHRQBZPOWQF-LTXDKZCQSA-N 1,3-di(decanoyloxy)propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC OCJAHRQBZPOWQF-LTXDKZCQSA-N 0.000 description 1
- BTLPCOOVNVTENY-NFYLBXPESA-N 1,3-di(octanoyloxy)propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC BTLPCOOVNVTENY-NFYLBXPESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GACTWZZMVMUKNG-KVTDHHQDSA-N D-mannitol 1-phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O GACTWZZMVMUKNG-KVTDHHQDSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 101100108073 Drosophila melanogaster Actn gene Proteins 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-O L-tyrosiniumyl-L-arginine(1+) Chemical compound NC(=[NH2+])NCCC[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-O 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- GNMSLDIYJOSUSW-LURJTMIESA-N N-acetyl-L-proline Chemical compound CC(=O)N1CCC[C@H]1C(O)=O GNMSLDIYJOSUSW-LURJTMIESA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- DGYBMJWDHSYLBQ-UHFFFAOYSA-M P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[K+] Chemical compound P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[K+] DGYBMJWDHSYLBQ-UHFFFAOYSA-M 0.000 description 1
- BSZBUWZYEDZOFY-UHFFFAOYSA-M P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[Na+] Chemical compound P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[Na+] BSZBUWZYEDZOFY-UHFFFAOYSA-M 0.000 description 1
- PFUQMGKMDZXLHP-UHFFFAOYSA-L P(=O)([O-])([O-])O.[Mg+2].C(C(O)CO)(=O)O Chemical compound P(=O)([O-])([O-])O.[Mg+2].C(C(O)CO)(=O)O PFUQMGKMDZXLHP-UHFFFAOYSA-L 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- GACTWZZMVMUKNG-JGWLITMVSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)COP(O)(O)=O GACTWZZMVMUKNG-JGWLITMVSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- ARJXIGOIOGJAKR-LURJTMIESA-N ethyl L-methioninate Chemical compound CCOC(=O)[C@@H](N)CCSC ARJXIGOIOGJAKR-LURJTMIESA-N 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 101150017109 fliA gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 235000009491 menaquinone-4 Nutrition 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 229960005481 menatetrenone Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- UIHPNZDZCOEZEN-YFKPBYRVSA-N methyl (2s)-2-amino-4-methylsulfanylbutanoate Chemical compound COC(=O)[C@@H](N)CCSC UIHPNZDZCOEZEN-YFKPBYRVSA-N 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920006284 nylon film Polymers 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- IUEMQUIQAPPJDL-UHFFFAOYSA-M sodium;2,3-dihydroxypropanoate Chemical compound [Na+].OCC(O)C([O-])=O IUEMQUIQAPPJDL-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
- A61J1/2034—Separating means having separation clips
Definitions
- the present invention relates to an infusion preparation containing a fat emulsion, a sugar, an amino acid, a bulk and vitamins, and a container and an IM preparation used for preparing the preparation. More specifically, (1) an infusion formulation containing fat emulsion, sugar and certain vitamins, (2) an infusion formulation containing amino acids, wisteria and other vitamins, and (3) the infusions described in (1) and (2) above. BACKGROUND OF THE INVENTION
- the administration of infusions to the feeding vessel by intravenous injection Have been done.
- examples of such an infusion include an aqueous solution containing a reducing agent i, an amino acid containing essential amino acids, an infusion of a mineral containing minerals, a fat emulsion containing a vegetable oil emulsion, and the like.
- Mixed vitamin preparations and the like are commercially available, and these infusion preparations are used by mixing them once and for all according to the patient's symptoms.
- fat emulsions are unstable formulations, and when mixed with other infusions, fat particles and oil separation are liable to cause phase separation (creaming). Especially, it is contained in Xiao Qian Infusion Divalent metal ions cause agglomeration of fat emulsions and disintegration of particles.
- the infusion of liquids involves the power of calcium and phosphoric acid, which is necessary to maintain the balance of water, and the formation of calcium phosphate by the combination of phosphoric acid and calcium. Tends to occur.
- the transfusion is usually adjusted to a low pH (less than pH 5).
- a low pH e.g. pH 5
- the pH is dominated by the amino acid side due to the strong and buffering action of the amino acid ⁇ a large amount of acid (eg, , Hydrochloric acid, acetic acid, etc.). Since a large amount of powder disturbs the balance of « ⁇ 3 ⁇ 4 ⁇ 3 ⁇ 4", the amount of powder used is limited, and the infusion cannot be reduced to a low pH.
- turbidity is liable to occur in the case of filamentous bacteria.
- the present inventors have intensively studied a method for preparing a stable infusion preparation containing a sugar, an amino acid, orchid, and a fat emulsion. It was found that infusions containing sugar, amino acids, orchid and fat emulsions were obtained in the forehead when used, and that various problems such as 3 ⁇ 43 ⁇ 4 ⁇ 3 ⁇ 4, alteration, and coloring could be solved. That is, a container in which two private compartments are formed by concealment means is used, the first compartment contains an infusion containing fat emulsion and sugar, and the second compartment contains an infusion containing amino acid and TO substance.
- vitamins are unstable to " ⁇ ", and the combination of certain vitamins can cause degradation and turbidity of the liquid. For example, we have found that when folic acid and vitamin c are mixed, turbidity is generated, Vitamin C has been found to degrade vitamin B 12 ⁇ 3 ⁇ 41 and other findings, and the group of vitamins ⁇ "if it is necessary to pay enough innocence IJ said.
- vitamins are water-soluble and fat-soluble, both of which have a great difference in physical properties. In particular, water-soluble vitamins are unstable.
- the transfer container of the present invention made to solve the above-mentioned problem is a container in which two private compartments are formed by an isolation means, and the first compartment contains a fat emulsion, sugar, vitamin (:, vitamin B, vitamin B 2, Bitamino, vitamin 0, are accommodated infusion containing vitamin E and vitamin K, also in the second chamber amino acids, Shikashitsu, vitamin B 6, vitamin B, 2 ⁇ The infusion solution containing D ⁇ is housed in.
- the isolation means is removed at the time of use, and the first and second chambers are lit and housed in the first room.
- an infusion containing a fat emulsion, sugar, amino acid, diluent and vitamin can be prepared.
- the average particle size of the fat emulsion contained in the Preferably, also accommodated in the second chamber! ⁇
- the force Ku good preferable to incorporate phosphate ester or a salt thereof polyhydric alcohol or sugar as test source of phosphorus.
- the infusion agent of the present invention removes the infusion agent contained in the first and second chambers of the container containing the infusion of ⁇ 1 and the means for isolating the li ⁇ A container. It is a car agent obtained by this.
- both the first chamber fat emulsion and sugar and less vitamin C, vitamin B,, vitamin B 2, vitamin A, vitamin D, sickle containing vitamin E and vitamin K accommodated Is done.
- a 3 ⁇ 4 ⁇ representing the vitamins and vitamin B 2, vitamin (B,, B 2) to give the title as.
- Fat emulsion an underwater emulsion prepared by dispersing fats and oils in water using an emulsifier is used.
- Fat emulsions can be prepared according to a conventional method.For example, after adding fats and oils and an emulsifier to water, stirring is performed to prepare a coarse emulsion, and then the coarse emulsion is subjected to a high-pressure emulsification method. Can be obtained by emulsification.
- oils and fats can be used as long as they are tffl oil, such as vegetable oils (eg, oil, cottonseed oil, safflower oil, corn oil, coconut oil, perilla oil, perilla oil, etc.), fish oil (eg, Cod liver oil, etc.), medium-potency triglycerides [eg, panassate (trade name), ODO (trade name), etc.] and chemically synthesized triglycerides [eg, 2-linoleoyl-1,3-dioctanoylglycerol (8L8), chemically defined triglyceride forces such as 2-linoleoyl-1,3-didecanoylglycerol (10L10), etc., where 13 ⁇ 4X is 23 ⁇ 4J: fats and oils Force is preferably used.
- vegetable oils eg, oil, cottonseed oil, safflower oil, corn oil, coconut oil, perilla oil, perilla oil, etc.
- fish oil eg
- any emulsifier can be used as long as it is an emulsifier which can be converted into an agent.
- egg yolk phospholipid, hydrogenated egg yolk phospholipid, short phospholipid, hydrogenated ⁇ phospholipid and nonionic Surfactant for example, pull mouth nick F68, HC O-60 (all are trade names), etc.] 1®X selected is 2 @ J3 ⁇ 4 ⁇ .
- a fat emulsion using oil as a fat or oil and egg yolk phospholipid as an emulsifier is used.
- the average particle diameter of the fat emulsion it is preferable to adjust the average particle diameter of the fat emulsion to 0.17 m or less.
- the fat emulsion of ⁇ * average particle size of 0.2 to 3 zm
- the stability can be enhanced.
- the phase separation of the fat emulsion caused by the difference in J fi can be effectively suppressed.
- Lipids with an average particle size of 0.17 m or less can be obtained by emulsifying 1 ⁇ X selected from glycerin and glucose at the time of preparing a fat emulsion by adding 2 SR: .
- a method is used in which oil and fat and a 1- L agent are added to water, followed by stirring to prepare a coarse emulsion, and then emulsifying the coarse emulsion by a high-pressure emulsification method or the like. Force With this method, it is difficult to easily obtain a milky ridge with an average particle size of 0.2 ⁇ m or less.
- the inventors have found that glycerin and glucose have a specific action of reducing micronization, and according to the above-mentioned production method, the average particle diameter is 0.1. Fat emulsions of 7 m or less can be prepared forehead.
- one example is to add fats and oils and an emulsifier to water, and add 2 kinds of 1MX selected from glycerin and glucose, and then stir the mixture. It is possible to prepare a fat emulsion by preparing an emulsion and then emulsifying the coarse emulsion by a conventional method of high pressure emulsification.
- the above Chichii ⁇ carried out in a high pressure emulsification method ⁇ for example, using the milk I ⁇ such Manton Gaulin homogenizer, the crude emulsion of 2 0 ⁇ 7 0 0 k gZ cm 2 ⁇ conditions, 5-5 0 This is done by putting together the rounds.
- glycerin and Z or glucose may be covered when emulsifying.
- glycerin and / or glucose is added to a coarse emulsion prepared from fats and oils and an emulsifier to emulsify. You may.
- the average particle size of the obtained Gakuho IJ can be measured by using a conventional measuring method such as a light scattering method.
- the amount of fats and oils, emulsifier, glycerin and Z or glucose in the obtained fat emulsion was 1 to 30 W / V% (hereinafter, unless otherwise specified,% is wzv %), Preferably 1 to 20% cereal, a milking agent 0.01 to 10%, preferably 0.05 to 5% ⁇ , dariserin and / or glucose 30 to 7 Ffl is adjusted so that it consists of 0% ⁇ , preferably 40-60% water and ⁇ * water.
- sugar contained in ⁇ which is stored in the first room various sugars can be blended.
- the ability to do so and the suitability to use are preferably used.
- suitable for use for example, glucose, fructose, maltose, and the like may be used in a mixture of the above two. Further, a mixture obtained by adding sorbitol, xylitol, glycerin, or the like to the above may be used.
- the first compartment at least vitamin as vitamin (C, B,, B 2 , A, D, E, K) are contained power Ku.
- vitamin C The strength and strength of the vitamin may be induced, and specific examples of vitamin C include ascorbic acid, sodium ascorbate, ascorbic acid palmitate, ascorbic acid dipalmitate, and magnesium ascorbate phosphate.
- vitamin B as the thiamine hydrochloride, prosultiamine, etc. Akutochiamin is, as the vitamins B 2 phosphate Ribofurabisu flavin mononucleotide and flavin adenine dinucleotide, Roh, as vitamin A. Retinol noremitate, etc., Cholecalcifrol (D 3 ) and Ergocalciferone monole (D 3 ) as vitamin D, d 1-tocopherol, 1 ⁇ tocophere as vitamin E, etc.
- Vitamin K includes fitnadione, menatetrenone, menadione, and the like.
- the preparation of f3 ⁇ 4 to be accommodated in the first chamber can be performed by various methods, for example, sugar may be added to the fat emulsion prepared by the above method, and sugar is added in advance when preparing the fat emulsion. You may keep it. Vitamin (C,, B 2, A , D, E, K) as ⁇ Ka Fong method of fat-soluble vitamins [vitamins (A, D, E, K ) ] can if dissolved in advance oil fat . In addition, vitamins (C, B, and B 2 ) may be dissolved in the thigh water at the time of preparation with the injection water after preparation of the emulsion.
- the amount of fat emulsion and sugar in the first chamber is reduced to the volume of the body (ie, the infusion solution containing amino acids, vitamins and vitamins) contained in the second chamber, and to the first and second chambers.
- Adjustable force for example, fats and oils 0.
- the second room contains an infusion containing amino and S substances and at least vitamins (B 6 , B 12 ) and folic acid.
- amino acids various amino acids (essential amino acids, ⁇ , sub-amino acids) conventionally contained in amino acid transfusions for the purpose of filling the living body with nutrients are strongly cited.
- acids include acid, L-serine, L-tyrosine, L-glutamic acid, L-cysteine and the like.
- amino acids do not necessarily need to be used in the form of amino acids, and include inorganic acid salts (eg, L-lysine hydrochloride), organic acid salts (eg, L-lysine acetate, L-lysine malate, etc.).
- inorganic acid salts eg, L-lysine hydrochloride
- organic acid salts eg, L-lysine acetate, L-lysine malate, etc.
- An ester form capable of hydrolyzing in vivo eg, L-tyrosine methyl ester, L-methionine methyl ester, L-methionine ethyl ester, etc.
- N-substituted form eg, N- Acetyl-L-tryptophan, N-acetyl-L-cysteine, N-acetyl-L-proline, etc.
- SX are dipeptides (eg, L-tyrosyl-1-L-tyrosine) in which different amino acids are bound by peptide. , L-aralanyl-l-tyrosine, L-arginyl-l-L-tyrosine, L-tyrosyl-l-arginine, etc.).
- orchid examples include various lysates tt ⁇ used in infusions from Wei.
- various kinds of non-donations required to maintain the balance of biological functions ⁇ # ⁇ For example, sodium, potassium, canoledium, magnesium, iron, copper, manganese, iodine, phosphorus, etc. can be dissolved in water (eg, chloride, sulfate, acetate, gnoreconate, lactate, etc.).
- Can be A hydrate may be added to these water-soluble components.
- a phosphoric acid ester of polyhydric alcohol or sugar or a salt thereof is preferably used as a source of phosphorus.
- the phosphoric ester of polyhydric alcohol include glycerol phosphate, mannitol-1-phosphate, sorbitol-1-phosphate, and the like.
- sugar phosphates include glucose-16-phosphate, fructose-16-phosphate, and mannoth-16-phosphate.
- the salts of these phosphate esters include sodium salts, potassium salts and the like. Genus salts are preferably used.
- sodium glycerate is used as a preferred esterophosphate.
- Preferred fibers of wisteria are as follows:
- Potassium chlorinated lime, potassium glycerate phosphate, sulfuric acid lime, potassium sulphate, potassium sulphate
- Canoleum gnoreconic acid canolecium, Shioridani caneoleum,
- Magnesium Magnesium sulfate, Magnesium chloride,
- Phosphorus Glycerium phosphate, glycerophosphate sodium, glycerate magnesium phosphate, glycerophosphate calcium ⁇ : Sulfur «I &, &, Glucone ⁇ «, milk ffii &, vinegar
- the second room contains at least vitamins as vitamins ( B 6, B, 2) and Nasan are included.
- Vitamin B 6 may be pyridoxine hydrochloride, pyridoxal phosphate, pyridoxamine phosphate, or the like, and vitamin B 6 may be cyanocobalamin or vitamin B i 2 . ⁇ Hydroxocobalamin, methylcobalamin and the like.
- the haze contained in the second chamber can be prepared by various methods, for example, by dissolving various amino acids and substances to be mixed in purified water such as measurement water. As a method of adding vitamins (B 6 , B 12 ) and, it is only necessary to add and dissolve at the same time as the dissolution of amino acids and protein.
- amino acids and TO in the second chamber depends on the concentration of the infusion contained in the first chamber (ie, the infusion containing lunar fat emulsion, sugar and vitamins), and the infusion into the first and second chambers. * Jt, etc .; ⁇ Adjustable force ⁇
- amino acids 1 preferably about 2 to 13%, more preferably about 3 to 12%, as a substance, sodium 50 to 18 OmEqZ ⁇ , potassium 40 to 135 mE q £ ⁇ , calcium 10 to 5 OmEq / ⁇ fi ⁇ .
- force that can be adjusted Preferably, when the infusions contained in the first and second chambers are mixed, the infusion is adjusted so as to include the following thread!
- Emulsifier 0.5 1 0 / a
- Each beta ⁇ of vitamin in the present invention formulation 1 dosage unit per vitamin ⁇ 2 l ⁇ 1 0mg, vitamin B 6 1 to 1 Omg, Bruno, ° Ntoten acids 5 to 25 mg, vitamin C 50 to 250 mg, Vitamin l ⁇ 10mg, Vitamin B 12 1 ⁇ 30 ⁇ g, 100 ⁇ 10000 ⁇ g, Piotin 20 ⁇ 300zg, Nicotimi 10 ⁇ 5 Omg, Vitamin A 2000 ⁇ 5000 IU, Vitamin D 200 ⁇ 10000 IU Vitamin E 5 ⁇ 20 IU, vitamin 0.2 ⁇ 10mg The ratio is good.
- the liquid properties of the haze contained in the first and second chambers are not particularly limited, but the pH is 5.0 to 8.0, preferably 5.5 to 7.0 from the aspect of the body's ⁇ ft. It is good to adjust to.
- the fiber contained in the second chamber uses a polyhydric alcohol or a phosphate ester of sugar or a salt thereof as a source of phosphorus, a relatively high pH value is required. It can be effectively suppressed.
- the pH observation IJ used for adjusting the pH of each of the above transfusions is not particularly limited as long as it is physiologically acceptable, and the ability to convert various acid agents is preferably an organic acid.
- the organic acid include cunic acid, gluconic acid, lactic acid, apple, maleic acid, and malonic acid. Is done.
- Infusions contained in the first and second chambers may be added with anti-coloring agents (eg, thioglycerol, dithiothreitol, etc.) to prevent coloring during sterilization and storage.
- anti-coloring agents eg, thioglycerol, dithiothreitol, etc.
- the amount of the inhibitor added is usually 1% or less.
- Coloring inhibitors may be added to both the first chamber infusion and the second chamber infusion.
- a buffer such as L-histidine or tris (hydroxymethyl) aminomethane may be added to the infusion stored in the first chamber, and the amount of these added is usually 1% or less.
- thioglycerol, sodium bisulfite, sodium sulfite, or the like may be added as an antioxidant to the infusion stored in the second chamber. The amount of these additives is usually 0.001% to 0.1%.
- those previously sterilized by heating bacteria or the like may be aseptically sealed in each chamber, but preferably the first and second chambers are sealed.
- a method is used in which the solution is sealed in a male chamber (Sf or under an inert gas) and sealed, and then sterilized. Sterilization can be performed according to a conventional method. For example, it is possible to perform sterilization by a fiber-filling method such as high-pressure steam fiber sterilization, hot water immersion sterilization, and hot water shower sterilization.
- Examples of the container used in the present invention include a glass container and a container made of plastic (eg, polypropylene, polyethylene, ethylene-vinyl copolymer #k polyvinyl chloride, polyamide, polyester, etc.).
- a flexible container made of a plastic film or sheet is preferably used as the material for the crane U plastic film and sheet.
- the container is preferably a container made of a material that can withstand the bacterium.
- the container has a light-shielding property.
- FIG. 1 is a schematic view showing an example of a fiber-containing container of the present invention.
- Figure 2 shows the book It is the schematic which shows the other Example of the container containing the infusion of this invention.
- FIG. 3 is a schematic view showing another example of the container for infusion of the present invention.
- FIG. 1 is a schematic view showing one difficult example of the fibrous container of the present invention.
- the container 1 is made of a material such as a plastic film (including a sheet, the same applies hereinafter) and has two private chambers, a first chamber 2 and a second chamber 3.
- First chamber month effect ⁇ agent is 2 and sugar and vitamins (C, B,, B 2 , A, D, E, K) ( hereinafter referred to as the first chamber vitamins) ⁇ 4 is housed containing
- the second compartment 3 contains an infusion solution 5 containing amino acids and proteins, vitamins (B 6 , B 12 ) and citrate (hereinafter referred to as the second compartment vitamins).
- the first chamber 2 and the second chamber 3 are provided in a section 6 for mixing them so that the carcinoma 4 contained in the first chamber 2 and the infusion solution 5 contained in the second chamber 3 do not mix.
- Pinch cock 7th grade! ⁇ Hidden by means.
- the container 1 has a port 8 for injecting the infusion 4 into the first chamber 2, a port 9 for injecting the infusion 5 into the second chamber 3, and a port 9 for taking out the infusion after mixing. There are 10 ports. If necessary, other agents can be mixed in from these ports.
- the above-mentioned infusion-containing container is obtained as follows. First, the part 6 of the container 1 is shut off by a separating means such as a pinch cock 7 so that the first chamber 2 and the second chamber 3 are connected to each other. An infusion containing vitamins is infused into chamber 1 and contains amino acids, 3 ⁇ 4 ⁇ -quality and vitamins in chamber 2 via port 9. The infused solution is injected into the second chamber 3. At this time, if necessary, nicotinic acid and / or pantothenic acid / biotin may be added to the infusion contained in the first chamber 2 and Z or the second chamber 3.
- a separating means such as a pinch cock 7
- the injection of the needles 4 and 5 into the first chamber 2 and the second chamber 3 is performed under a stream of an inert gas (for example, nitrogen gas, argon gas, or the like).
- an inert gas for example, nitrogen gas, argon gas, or the like.
- the ports 8 and 9 are sealed, respectively, and then sterilized to obtain the preserving container shown in FIG. .
- Sterilization can be performed according to a conventional method.
- sterilization can be performed by a fiber-containing method such as high-pressure steam sterilization, hot water immersion sterilization, or hot water shower sterilization.
- the ⁇ used is preferably strong because it is sterilized under an atmosphere containing substantially no oxygen.
- the container of the present invention obtained by wrapping the container is difficult to store because of its difficulty.
- the pinch cock 7 is removed, and the first chamber 2 and the second chamber 3 are iii.
- mixing 4 and 5 it is possible to enhance the aseptic preparation of fat emulsions, sugars, amino acids, qualities and vitamins.
- the above-mentioned mixed infusion is aseptically removed from the port 8 via a tube (not shown) and administered to a living body.
- FIG. 2 is a schematic view showing another embodiment of the container containing the present invention.
- a container 11 is made of a material such as a plastic film, and is separated by a screw cock 16 to form two private rooms, a first room 12 and a second room 13. .
- the first room 12 contains 14 fluids containing lipology, sugar and vitamins in the first room, and the second room 13 contains amino acids, exfoliates and vitamins in the second room. Since the first chamber 12 and the second chamber 13 are isolated by the screw cock 16 above, the infusion contained in the first chamber 12 Infusions contained in 14 and the second chamber 1'3 15 There is no mixing.
- the container 11 has a port 17 for injecting the haze 14 into the first chamber 12, a port 18 for injecting the infusion 15 into the second chamber 13, and an infusion after mixing. There is a port 19 to take out the power. If necessary, it is possible to mix other drugs through these ports.
- the manufacturing method and the conversion method of the j3 ⁇ 4A container shown in Fig. 2 are substantially the same as those of the container shown in Fig. 1.
- FIG. 3 is a schematic view showing another example of the container of the present invention. As shown in the figure, the container 21 is made of a material such as a plastic film, and the film constituting the container is separated by the heat-sealing ⁇ ⁇ 3 ⁇ 4 ⁇ 28 to form the first chamber.
- Two private chambers 22 and a second chamber 23 are formed. ⁇ ⁇ 3 ⁇ 48 is formed to be separable by applying external force.
- the first chamber 22 contains a fiber 24 containing fat emulsion, sugar and first-chamber vitamins, and the second chamber 23 contains amino acids, high-quality and second-chamber vitamins.
- Infusion solution 2 5 force ⁇ stored force ffl] The first room 22 and the second room 23 are separated by the band 28, so they are housed in the first room 22 4 and the infusion contained in the second chamber 23 will not mix.
- the container 21 is provided with a port 26 for supplying! 24 to the first chamber 22 and a port 27 for injecting the infusion solution 25 into the second chamber 23. Have been. If necessary, it is possible to mix in these ports.
- the port 26 or 27 can be used for taking out the infusion.
- the infusion container shown in Fig. 3 should be sealed in one of the first chamber 22 and the second chamber 23, which is isolated by ⁇ ⁇ 3 ⁇ 428, and then inverted. Manufactured by fibering ⁇ Zong to ⁇ .
- the sterilization method and the ⁇ gffl method are substantially the same as those of the container shown in Fig. 1, but in this container, an external force is applied during use to separate the container. By opening, the infusions contained in the first chamber 22 and the second chamber 23 are mixed.
- the infusion container shown in FIG. 1, FIG. 2, and FIG. 3 is one embodiment of the present invention, and is not limited thereto.
- the plate and dimensions of the container can be changed, and the container body may be provided with a suspending portion for locking the transport container to a conventional suspending device.
- the means 1 is not limited to the above example.
- a clip or the like may be used instead of the pinch cock 7, and a ball stopper is provided in the ii® part 6.
- the first chamber and the second chamber may be separated by the same method.
- the container of the present invention may be subjected to oxygen incompatibility in order to prevent deterioration of the infusion solution in the container.
- oxygen impermeable film include a laminated film including an ethylene-vinyl alcohol copolymer film, a polyvinyl alcohol film, a polyvinylidene chloride film, or the like as an intermediate layer (for example, a polyester film as an outer layer, a stretched nylon film, a stretched film).
- Laminate film including non-evaporated film for example, polyester film-gay evaporated film-unstretched polypropylene film, stretched nylon film-gay evaporated film-unstretched polypropylene film, polyester film-
- an oxygen scavenger eg, Ageless, trade name
- a vacuum e.g., a gas
- a gas e.g. nitrogen gas, etc.
- ⁇ containing fat emulsion, sugar, amino acid, exfoliate and vitamins obtained by mixing the haze contained in the first and second chambers has male preservation, ⁇ « ⁇ 3 ⁇ 4, It can be stored for about one week without coloring.
- the solution may be administered intravenously to the patient as is or diluted with water, or as a senior at work, mixed with drugs as needed. Further, it can be used for oral and intravenous administration.
- the obtained coarse emulsion is washed with a Menton-Gaulin homogenizer (manufactured by Gorin, Model 15M-8TA).
- the emulsion was obtained by emulsification until the average particle diameter became 0.17 m or less. Water was added to 500 ml of the obtained emulsion to make ⁇ * 1 000 m ⁇ . Table 1 shows the infusions obtained.
- Nitrogen ⁇ Tf, amino acids, amino acids, and vitamins shown in Tables 2, 3 and 4 are added to and dissolved in water for measurement heated to about 80 ° C, and the mixture is dissolved in citric acid. The pH was adjusted to 6.2.
- a dish-made polypropylene container shown in FIG. 1 was used. After shutting off the part 6 with the pinch cock 7, the infusion solution 60 Om ⁇ containing the fat emulsion, sugar and vitamin obtained by Fiber (1) was ported to the first chamber 2 while the nitrogen gas was winged. After the injection, port 8 was sealed. On the other hand, the second room 3 contains the amino acids, ⁇ ⁇ substances and vitamins obtained above! ⁇ 300 m was injected from port 9 while supplying nitrogen gas, and port 9 was sealed after injection. The container 1 containing each infusion was subjected to high-pressure steaming (115 ° C, 30 minutes) and then allowed to reach room temperature to obtain the fliA container of the present invention.
- high-pressure steaming 115 ° C, 30 minutes
- the infusion solution obtained above was stored at 25 ° C. for one week, and during that time, the appearance and the change in the average particle removal turbidity of the fat emulsion were measured. Table 6 shows the results.
- As a control 300 ml of Nada water was injected into the second room 3, sterilized in the same manner, and a mixed infusion was used.
- the average particle size of the fat emulsion was measured by a light scattering method, and the turbidity was measured by absorption at 620 nm (1 cm cell).
- fat-soluble vitamins (A, D, E, and K) were added to the first chamber, and water-soluble vitamins (B, C, nicotinamide, pantothenol, and biotin) were added to the second chamber.
- B, C, nicotinamide, pantothenol, and biotin were added to the second chamber. The mode was also difficult.
- the two liquid chambers containing fat emulsion, sugar and vitamin, and amino acid, ⁇ ⁇ liquid containing vitamin and vitamin are vigorously pre-fiberized in two hidden chambers.
- an infusion solution which is excellent in stability and stability and does not require an operation of mixing a fat emulsion, a sugar, an amino acid, a vitamin, and a vitamin, so that the operation is simple.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Fluid Mechanics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1993628794 DE69328794T2 (de) | 1992-10-22 | 1993-10-21 | Behälter mit transfusionsflüssigkeit und verbereitete transfusionsflüssigkeit |
EP19930923041 EP0747033B1 (en) | 1992-10-22 | 1993-10-21 | Transfusion liquid-containing holder and prepared transfusion liquid |
KR1019950701531A KR100331583B1 (ko) | 1992-10-22 | 1993-10-21 | 주입제제 |
US09/032,843 US6129925A (en) | 1992-10-22 | 1998-03-02 | Container filled with infusion liquids and infusion preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30924992 | 1992-10-22 | ||
JP4/309249 | 1992-10-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/437,330 Continuation-In-Part US5770233A (en) | 1992-10-22 | 1995-04-21 | Container filled with infusion liquids and infusion preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994008548A1 true WO1994008548A1 (en) | 1994-04-28 |
Family
ID=17990730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001521 WO1994008548A1 (en) | 1992-10-22 | 1993-10-21 | Transfusion liquid-containing holder and prepared transfusion liquid |
Country Status (8)
Country | Link |
---|---|
US (2) | US5770233A (ja) |
EP (1) | EP0747033B1 (ja) |
JP (1) | JPH06209979A (ja) |
KR (1) | KR100331583B1 (ja) |
CA (1) | CA2147599A1 (ja) |
DE (1) | DE69328794T2 (ja) |
ES (1) | ES2146234T3 (ja) |
WO (1) | WO1994008548A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704199A1 (en) * | 1994-04-20 | 1996-04-03 | The Green Cross Corporation | Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69328794T2 (de) * | 1992-10-22 | 2000-11-09 | Yoshitomi Pharmaceutical | Behälter mit transfusionsflüssigkeit und verbereitete transfusionsflüssigkeit |
JPH0987177A (ja) * | 1995-09-20 | 1997-03-31 | Green Cross Corp:The | 安定なビタミンc製剤 |
JP4120018B2 (ja) | 1997-02-14 | 2008-07-16 | 味の素株式会社 | 2室容器入り経静脈用総合栄養輸液製剤 |
AU759894B2 (en) * | 1999-05-28 | 2003-05-01 | Novartis Ag | Package for a pharmaceutical product and method of sterilising the package |
US7678097B1 (en) | 1999-11-12 | 2010-03-16 | Baxter International Inc. | Containers and methods for manufacturing same |
US20050194060A1 (en) * | 2004-03-03 | 2005-09-08 | Vincent Houwaert | Peelable seal closure assembly |
DK1265496T3 (da) * | 2000-03-24 | 2006-03-20 | Adisseo France Sas | Flydende vitaminpræparat |
US7175614B2 (en) * | 2002-10-17 | 2007-02-13 | Baxter International Inc. | Peelable seal |
TWI319984B (en) * | 2003-06-06 | 2010-02-01 | Sterile combined preparation | |
JP2005179200A (ja) * | 2003-12-16 | 2005-07-07 | Terumo Corp | ビタミンb1類配合輸液剤 |
JP4894219B2 (ja) * | 2004-10-15 | 2012-03-14 | ニプロ株式会社 | ビタミンb群配合末梢静脈栄養輸液 |
ZA200802769B (en) * | 2005-09-29 | 2009-09-30 | Alcon Inc | Dual-chamber solution packaging system |
US9004761B2 (en) | 2006-05-01 | 2015-04-14 | Baxter International Inc. | Multiple chamber container with mistake proof administration system |
JP5769354B2 (ja) * | 2006-11-08 | 2015-08-26 | エイワイファーマ株式会社 | 中心静脈投与用輸液 |
JP2008290968A (ja) * | 2007-05-24 | 2008-12-04 | Otsuka Pharmaceut Factory Inc | 脂肪乳剤の安定化方法及び輸液バック |
MX2010000660A (es) * | 2009-12-11 | 2011-06-14 | Abbott Lab | Soluciones de rehidratacion oral que comprenden dextrosa. |
CN106924181A (zh) * | 2010-05-07 | 2017-07-07 | Ea制药株式会社 | 混合有维生素的外周静脉给药用营养输液 |
AU2015268572B2 (en) * | 2010-11-29 | 2017-09-07 | Otsuka Pharmaceutical Factory, Inc. | Infusion preparation |
EP2647370B1 (en) | 2010-11-29 | 2019-02-27 | Otsuka Pharmaceutical Factory, Inc. | Infusion preparation |
USD699343S1 (en) | 2011-12-20 | 2014-02-11 | Alcon Research, Ltd. | Irrigation solution bag |
DE102014202261A1 (de) * | 2014-02-07 | 2015-08-27 | Eurozyto Gmbh | Behältnis und Set zur Bereitstellung parenteraler Nahrung |
JP2017024727A (ja) * | 2015-07-16 | 2017-02-02 | 日立造船株式会社 | 密封バッグ、密封パッケージ、無菌充填システム及び密封パッケージの製造方法 |
CN111526730B (zh) | 2017-12-29 | 2024-02-23 | 卡夫食品集团品牌有限责任公司 | 使用天然稳定剂改善的水包油乳液的氧化稳定性 |
RU2721605C1 (ru) * | 2019-11-11 | 2020-05-21 | Общество с ограниченной ответственностью "Ай Кью Витаминная студия" | Фармацевтическая композиция для парентерального капельного введения |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58162515A (ja) * | 1982-03-19 | 1983-09-27 | Tanabe Seiyaku Co Ltd | 末梢静脈注入用加電解質アミノ酸輸液 |
JPH01240469A (ja) * | 1988-03-17 | 1989-09-26 | Material Eng Tech Lab Inc | 内容物入り容器 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2433173C3 (de) * | 1974-07-10 | 1980-02-07 | J. Pfrimmer & Co, 8520 Erlangen | Verwendung von Cholansaurederivaten |
US4000190A (en) * | 1975-02-10 | 1976-12-28 | Stauffer Chemical Company | Process for preparing alkyl- and aryl phosphonothioic dihalides |
JPS58162517A (ja) * | 1982-03-19 | 1983-09-27 | Green Cross Corp:The | 脂溶性ビタミン含有脂肪乳剤 |
JPH0748991B2 (ja) * | 1984-08-29 | 1995-05-31 | 日本油脂株式会社 | 経管栄養組成物 |
JPH0680008B2 (ja) * | 1985-12-09 | 1994-10-12 | 森夫 葛西 | 癌用アミノ酸輸液 |
KR920019370A (ko) * | 1991-04-26 | 1992-11-19 | 스야마 다다카즈 | 주입 제제 |
ES2188704T3 (es) * | 1991-04-26 | 2003-07-01 | Mitsubishi Pharma Corp | Recipiente relleno con liquidos de infusion. |
DE69328794T2 (de) * | 1992-10-22 | 2000-11-09 | Yoshitomi Pharmaceutical | Behälter mit transfusionsflüssigkeit und verbereitete transfusionsflüssigkeit |
KR100299630B1 (ko) * | 1993-01-19 | 2001-11-22 | 데이비드 씨. 맥키, 토마스 제어. 시바티노 | 다중챔버용기 |
-
1993
- 1993-10-21 DE DE1993628794 patent/DE69328794T2/de not_active Expired - Fee Related
- 1993-10-21 CA CA002147599A patent/CA2147599A1/en not_active Abandoned
- 1993-10-21 WO PCT/JP1993/001521 patent/WO1994008548A1/ja active IP Right Grant
- 1993-10-21 EP EP19930923041 patent/EP0747033B1/en not_active Expired - Lifetime
- 1993-10-21 JP JP28741993A patent/JPH06209979A/ja active Pending
- 1993-10-21 ES ES93923041T patent/ES2146234T3/es not_active Expired - Lifetime
- 1993-10-21 KR KR1019950701531A patent/KR100331583B1/ko not_active IP Right Cessation
-
1995
- 1995-04-21 US US08/437,330 patent/US5770233A/en not_active Expired - Fee Related
-
1998
- 1998-03-02 US US09/032,843 patent/US6129925A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58162515A (ja) * | 1982-03-19 | 1983-09-27 | Tanabe Seiyaku Co Ltd | 末梢静脈注入用加電解質アミノ酸輸液 |
JPH01240469A (ja) * | 1988-03-17 | 1989-09-26 | Material Eng Tech Lab Inc | 内容物入り容器 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704199A1 (en) * | 1994-04-20 | 1996-04-03 | The Green Cross Corporation | Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation |
EP0704199A4 (en) * | 1994-04-20 | 1998-04-22 | Green Cross Corp | TRANSFUSION CONTAINER, TRANSFUSION PREPARATION AND COMPREHENSIVE, VITAMIN CONTAINING, CALORIOUS PREPARATION |
Also Published As
Publication number | Publication date |
---|---|
DE69328794D1 (de) | 2000-07-06 |
EP0747033A1 (en) | 1996-12-11 |
CA2147599A1 (en) | 1994-04-28 |
KR100331583B1 (ko) | 2002-11-27 |
ES2146234T3 (es) | 2000-08-01 |
DE69328794T2 (de) | 2000-11-09 |
EP0747033A4 (en) | 1995-09-07 |
JPH06209979A (ja) | 1994-08-02 |
US6129925A (en) | 2000-10-10 |
KR950703922A (ko) | 1995-11-17 |
EP0747033B1 (en) | 2000-05-31 |
US5770233A (en) | 1998-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994008548A1 (en) | Transfusion liquid-containing holder and prepared transfusion liquid | |
EP0704199B1 (en) | Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation | |
US5674527A (en) | Infusion preparation comprising phospholipid | |
JP7438982B2 (ja) | Gpcを含有する非経口栄養のための脂質エマルション | |
EP0671166B1 (en) | Nutrient-supplying infusion | |
KR100374436B1 (ko) | 말초정맥투여용영양수액 | |
JP4162306B2 (ja) | 中心静脈投与用輸液 | |
JP2001079064A (ja) | 輸液入り容器 | |
JP4717170B2 (ja) | 栄養輸液製剤 | |
JP3097196B2 (ja) | 脂肪乳剤の安定化法 | |
JP3364932B2 (ja) | 輸液入り容器 | |
JP2007262088A (ja) | 栄養輸液製剤 | |
JP2004001900A (ja) | 中心静脈投与用輸液中のビタミン類の安定化方法 | |
JP3456536B2 (ja) | 輸液製剤 | |
JPH08709A (ja) | 輸液入り容器、輸液製剤及びビタミン配合総合高カロリー輸液製剤 | |
JP3711400B2 (ja) | 輸液製剤 | |
US20230172806A1 (en) | Multi-chamber bag for parenteral nutrition solutions | |
TWI794447B (zh) | 輸液製劑 | |
JP3430965B2 (ja) | 安定化された脂肪乳剤含有溶液 | |
JPH07178151A (ja) | 2室容器入り栄養輸液製剤 | |
WO2023117871A1 (en) | Compositions for providing parenteral nutrition to pediatric patients | |
JP2020152662A (ja) | 脂肪乳剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993923041 Country of ref document: EP Ref document number: 2147599 Country of ref document: CA Ref document number: 1019950701531 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1993923041 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993923041 Country of ref document: EP |